Neuroendocrine Gene Transcript Analysis of Blood Identifies Stable or Progressive NET Disease Treated with Somatostatin Analogs.
#1195
Introduction: An issue in NET management is defining stable or progressive disease and effective treatment. An alternative to RECIST criteria is a sensitive, reproducible blood biomarker test. Somatostatin analogs (SSA) are a chief therapy but efficacy is subjective and based on symptom control and imaging.
Aim(s): Investigate the utility of a PCR-based 51 gene signature (NETest) and CgA as biomarkers to define SSA efficacy.
Materials and methods: GEP-NETs (n=35) M:F 12:23; median age 58, small intestine n=29, pancreas n=3, rectum n=3 were evaluated. qRT-PCR measured transcript levles and ELISA (DAKO) for CgA. Clinical status and imaging was assessed. NETest defines disease activity risk scaled 0-100%; low and high activity cutoff at 47%.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author:
Authors: Alaimo D, Callahan S, Lepensky C, Jonzzon S, Teixeira N,
To read the full abstract, please log into your ENETS Member account.